Merck to invest 100 million Euros in biosimilars

Posted On 26 May 2014
By :



Recognising biosimilars as new sources of growth, Germany’s Merck KGaA is gearing up for more acquisitions, as well as searching for pharmaceutical in-licensing deals and planning to invest around Euros 100 million in biosimilars. The move comes in the wake of news that Merck’s top-selling drug Rebif (interferon beta-1a), an injectable multiple sclerosis treatment, is gradually being replaced by new orally administered drugs such as Biogen Idec’s Tecfidera (dimethyl fumarate).

Read the source article at

About the Author

Leave a Reply